Aurobindo Pharma Outperforms Expectations with Strong Q4, Eyes Robust Growth Ahead

Aurobindo Pharma (NS:ARBN) has outperformed expectations in the fourth quarter of FY24, with both sales and EBITDA showing significant year-over-year growth. Sales increased by 17%, while EBITDA surged by an impressive 68%, surpassing both Goldman Sachs (NYSE:GS)' projections and those of the broader market. The EBITDA margin also exceeded forecasts, reaching 22.3%, which is 101 basis points higher than Goldman Sachs' estimate.